Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNovo Nordisk A/S Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | $5.48 | $6.07 | $5.79 |
| Q2 2026 | 1 | $5.20 | $5.76 | $5.49 |
| Q3 2026 | 1 | $4.66 | $5.16 | $4.92 |
| Q4 2026 | 1 | $4.92 | $5.45 | $5.20 |
| Q1 2027 | 1 | $5.12 | $5.67 | $5.40 |
| Q2 2027 | 1 | $4.76 | $5.27 | $5.03 |
| Q3 2027 | 1 | $4.55 | $5.04 | $4.80 |
| Q4 2027 | 1 | $4.71 | $5.21 | $4.97 |
Novo Nordisk A/S Earnings Date And Information
Novo Nordisk A/S last posted its earnings results on Wednesday, November 5th, 2025. The company reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.77 by $0.25. The company had revenue of 74.98 B for the quarter and had revenue of 290.40 B for the year. Novo Nordisk A/S has generated $23 earnings per share over the last year ($22.63 diluted earnings per share) and currently has a price-to-earnings ratio of 15.98. Novo Nordisk A/S has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 4th, 2026 based on prior year's report dates.
Novo Nordisk A/S Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2025 | Q3 2025 | $0.77 | $4.50 | 3.73 | $76.03 B | $74.98 B |
| 08/06/2025 | Q2 2025 | $0.93 | $5.96 | 5.03 | $75.85 B | $76.86 B |
| 05/07/2025 | Q1 2025 | $0.92 | $6.54 | 5.62 | N/A | $78.09 B |
| 02/05/2025 | Q4 2024 | $0.88 | $6.34 | 5.46 | N/A | $85.68 B |
| 09/28/2024 | Q3 2024 | N/A | $6.13 | N/A | $70.57 B | $71.31 B |
| 06/29/2024 | Q2 2024 | N/A | $4.50 | N/A | $69.28 B | $68.06 B |
| 03/30/2024 | Q1 2024 | N/A | $5.70 | N/A | N/A | $65.35 B |
| 12/30/2023 | Q4 2023 | N/A | $4.92 | N/A | N/A | $65.86 B |
| 09/29/2023 | Q3 2023 | N/A | $5.02 | N/A | N/A | $58.73 B |
| 06/29/2023 | Q2 2023 | N/A | $4.33 | N/A | N/A | $54.30 B |
| 03/31/2023 | Q1 2023 | N/A | $4.40 | N/A | N/A | $53.37 B |
| 12/30/2022 | Q4 2022 | N/A | $3.02 | N/A | N/A | $48.09 B |
| 09/29/2022 | Q3 2022 | N/A | $3.17 | N/A | N/A | $45.57 B |
| 06/29/2022 | Q2 2022 | N/A | $2.93 | N/A | N/A | $41.27 B |
| 03/30/2022 | Q1 2022 | N/A | $3.11 | N/A | N/A | $42.03 B |
| 12/30/2021 | Q4 2021 | N/A | $2.38 | N/A | N/A | $38.33 B |
| 09/29/2021 | Q3 2021 | N/A | $2.65 | N/A | N/A | $35.62 B |
| 06/29/2021 | Q2 2021 | N/A | $2.63 | N/A | N/A | $33.04 B |
| 03/30/2021 | Q1 2021 | N/A | $2.74 | N/A | N/A | $33.80 B |
| 12/30/2020 | Q4 2020 | N/A | $2.01 | N/A | N/A | $32.14 B |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Novo Nordisk A/S Earnings: FAQ's
Novo Nordisk A/S has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 4th, 2026 based offlast year's report dates.
In the previous quarter, Novo Nordisk A/S (:NVO) reported $1.02 earnings per share (EPS) to beat the analysts' consensus estimate of $0.77 by $0.25.
The conference call for Novo Nordisk A/S's latest earnings report can be listened to online.
The conference call transcript for Novo Nordisk A/S's latest earnings report can be read online.
Novo Nordisk A/S (:NVO) has a recorded annual revenue of $290.40 B.
Novo Nordisk A/S (:NVO) has a recorded net income of $100.99 B.Novo Nordisk A/S has generated $22.67 earnings per share over the last four quarters.
Novo Nordisk A/S (:NVO) has a price-to-earnings ratio of 15.98 and price/earnings-to-growth ratio is -2.45.